Myeloma is a serious blood cancer, but survival rates have improved significantly in the last decade

Multiple myeloma is a cancer of plasma cells in the bone marrow. It damages bone, interferes with immune function, and affects kidney health. The disease is incurable with current treatments, but many people live for years after diagnosis—some for 10 years or longer. How serious it is for any one person depends on the stage at diagnosis, age, overall health, and how the cancer responds to treatment.

The five-year survival rate for myeloma is now around 60 percent, meaning about 6 in 10 people diagnosed are alive five years later. This is a substantial improvement from 20 years ago, when the rate was closer to 30 percent. The improvement comes from newer drugs and combination therapies that work better than older chemotherapy alone.

Key Takeaways

  • Myeloma is incurable but treatable, with many people living 5 to 10 years or longer after diagnosis depending on stage and response to therapy.
  • Survival rates vary widely based on age, kidney function, calcium levels, and genetic markers in the cancer cells—your doctor can estimate your individual prognosis.
  • Newer drugs called proteasome inhibitors and immunomodulatory drugs have extended survival compared to older chemotherapy regimens.
  • Early-stage myeloma may not require immediate treatment, but advanced disease typically needs combination therapy to control symptoms and slow progression.

How doctors measure how advanced your myeloma is

Myeloma is staged using the Revised International Staging System (R-ISS), which sorts patients into three groups based on blood test results and genetic markers. Stage 1 has the best prognosis; stage 3 has the worst. Doctors also look at whether the cancer is in one bone (solitary plasmacytoma) or multiple bones (disseminated disease).

The tests that determine stage include hemoglobin level, calcium level, kidney function, and LDH (a protein that rises when cells break down). Genetic testing of the cancer cells themselves—looking for high-risk mutations—also shapes the picture. A person diagnosed at stage 1 with favorable genetics may have a median survival of 10 years or more, while stage 3 with high-risk features may be 3 to 5 years. These are medians, not guarantees; individual outcomes vary.

What happens in the first months after diagnosis

Not everyone needs treatment immediately. If you have myeloma but few or no symptoms, normal kidney function, and low calcium levels, your doctor may recommend "watch and wait"—regular blood tests and imaging without chemotherapy. This approach avoids side effects while the disease is stable. Treatment begins when the cancer starts causing organ damage, bone pain, anemia, or kidney problems.

When treatment does start, it usually involves a combination of three drugs: a proteasome inhibitor (like bortezomib), an immunomodulatory drug (like lenalidomide), and a corticosteroid (like dexamethasone). This combination is more effective than any single drug. Many people respond well in the first few months, with blood markers dropping sharply. Response to initial therapy is one of the strongest predictors of how long remission will last.

Remission, relapse, and what comes next

After initial treatment, the goal is remission—a state where the cancer is controlled and blood markers are low or undetectable. Remission is not the same as cure. Myeloma almost always returns at some point, though the time between remission and relapse can be months or years. When it does return, treatment usually resumes with the same drugs or different ones, depending on how long the first remission lasted and whether the cancer became resistant.

People often go through multiple cycles of remission and relapse over many years. Each relapse is treated, and many respond again. Newer drugs have made it possible to manage multiple relapses, extending overall survival. The pattern and timing of relapses varies widely—some people have long remissions between treatments, others shorter ones.

Side effects and quality of life during treatment

Myeloma drugs cause side effects that affect daily life. Proteasome inhibitors can cause neuropathy (nerve damage in the hands and feet), fatigue, and low blood counts. Immunomodulatory drugs increase the risk of blood clots and can cause constipation or rash. Corticosteroids cause sleep problems, mood changes, and increased appetite. These side effects are usually manageable with other medications or dose adjustments, but they are real and worth discussing with your oncology team.

Many people continue working, caring for family, and doing activities they enjoy during treatment, though energy levels often drop. Some side effects improve after treatment ends; others, like neuropathy, may be permanent. Your doctor can help you weigh the benefit of a particular drug against its side effects and sometimes switch to alternatives if a side effect becomes intolerable.

Factors that change the outlook

Age matters. People under 65 tend to tolerate intensive treatment better and often live longer after diagnosis than those over 75, though age alone does not determine outcome. Kidney function at diagnosis is critical—if your kidneys are already damaged, the cancer is harder to treat and prognosis is worse. Genetic markers in the cancer cells (high-risk mutations like del(17p) or t(4;14)) predict faster progression and shorter survival, but even these are not absolute.

How well your cancer responds to the first treatment is one of the strongest predictors of what comes next. If blood markers drop quickly and stay low, you are likely to have a longer remission. If the cancer is slow to respond or resistant from the start, the outlook is more guarded. Your doctor can discuss these factors with you after initial testing and after you see how your cancer responds to treatment.

Clinical trials and newer treatment options

Myeloma treatment is evolving. Newer drugs like CAR-T cell therapy (where your own immune cells are engineered to fight the cancer) and bispecific antibodies are showing promise in people whose cancer has relapsed multiple times. These are often available through clinical trials. If your cancer stops responding to standard drugs, asking your oncologist about trial options is worth doing—trials sometimes offer access to treatments not yet widely available.

The landscape of myeloma treatment has changed dramatically in the past 10 years, and it continues to change. Drugs approved in the last few years have extended survival for people with difficult-to-treat disease. This means that a prognosis given at diagnosis may be more pessimistic than what actually happens, especially if you are treated with newer regimens.

Frequently Asked Questions

Is myeloma always fatal?

Myeloma is incurable with current treatments, meaning it will eventually return after remission. However, many people live for years or decades after diagnosis, managing the disease with repeated rounds of treatment. Some die from myeloma; others die from unrelated causes while living with stable disease.

Can myeloma go into remission?

Yes. Most people respond to initial treatment and enter remission, where blood markers drop and symptoms improve. Remission can last months to years. The cancer typically returns eventually, but remission can be achieved again with further treatment.

What is the difference between myeloma and multiple myeloma?

Multiple myeloma means the cancer is in multiple bones or areas of the bone marrow. Solitary myeloma or plasmacytoma is a single tumor, which is rarer and sometimes has a better prognosis. Most people diagnosed have multiple myeloma.

Does age affect how serious myeloma is?

Age affects treatment options and tolerance, but not the cancer itself. Younger people often receive more intensive treatment and tend to live longer after diagnosis. Older people may receive gentler regimens. Individual health and how the cancer responds matter as much as age.

What should I ask my oncologist about my specific prognosis?

Ask about your stage, genetic markers, and what the median survival is for someone with your specific combination of factors. Ask how your cancer responded to initial treatment and what that means for the next phase. Ask about side effects you can expect and how they are managed. Ask what happens if the cancer stops responding to your current drugs.